Synapse - Works

Results (115370)

Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial

Meeting Abstract

Harter, P.; Trillsch, F.; Okamoto, A.; Reuss, A.; Kim, J. W.; Rubio-Pérez, M. J.; Vardar, M. A.; Scambia, G.; Tredan, O.; Nyvang, G. B.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC

Meeting Abstract

Wakelee, H. A.; Liberman, M.; Kato, T.; Tsuboi, M.; Lee, S. H.; He, J.; Gao, S.; Chen, K. N.; Dooms, C. A.; Majem, M.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results

Meeting Abstract

Meric-Bernstam, F.; Makker, V.; Oaknin, A.; Oh, D. Y.; Banerjee, S. N.; Martin, A. G.; Jung, K. H.; Lugowska, I. A.; Manso, L.; Manzano, A.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study

Meeting Abstract

Choueiri, T. K.; Albiges, L.; Tomczak, P.; Suáez, C.; Voss, M. H.; de Velasco, G.; Chahoud, J.; Procopio, G.; Mahammedi, H.; Zengerling, F.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Primary overall survival analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel versus standard-of-care therapy in relapsed/refractory large B-cell lymphoma

Meeting Abstract

Westin, J.; Oluwole, O. O.; Kersten, M. J.; Miklos, D. B.; Perales, M. A.; Ghobadi, A.; Rapoport, A.; Sureda, A.; Jacobson, C. A.; Farooq, U.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study

Meeting Abstract

Yang, J. C. H.; Lee, D. H.; Lee, J. S.; Fan, Y.; de Marinis, F.; Okamoto, I.; Inoue, T.; Cid, J. R. R.; Zhang, L.; Yang, C. T.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048)

Meeting Abstract

Schrag, D.; Shi, Q.; Weiser, M. R.; Gollub, M. J.; Saltz, L. B.; Musher, B. L.; Goldberg, J.; Al Baghdadi, T.; Goodman, K. A.; McWilliams, R. R.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation

Meeting Abstract

Mellinghoff, I. K.; Van Den Bent, M. J.; Blumenthal, D. T.; Touat, M.; Peters, K. B.; Clarke, J. L.; Mendez, J. S.; Welsh, L.; Mason, W. P.; Hottinger, A. F.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Body mass index mediates the direct association of subjective social status and hypertension in a Fulani West African immigrant sample

Journal Article

Rasmussen, A.; Burke, N. L.; Cisse, A.; Ahmed, S.; Romero, S.; Gany, F.
American Journal of Orthopsychiatry (2023)

Fulltext@MSK | Save

Guidelines for reporting observational research in urology: The importance of clear reference to causality

Editorial

Vickers, A. J.; Assel, M.; Dunn, R. L.; Zabor, E. C.; Kattan, M. W.; van Smeden, M.; Dahly, D.
Urology (2023)

Fulltext@MSK | Save